Researchers are interested in identifying "exceptional responders" to cancer medications to help highlight biomarkers that will identify patients likely to respond to treatment.
According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.
According to the AACI, proposed budget cuts by the White House would likely mean a cut of close to $1 billion for the National Cancer Institute.
Pediatric Cancer News
If value is hard to define because it is perceived differently by different people, how can oncologists and policymakers accurately gauge cost-effectiveness?
Clinicians are advocating that sexual dysfunction after cancer, which affects a large proportion of survivors, be addressed as a serious quality of life issue.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA 1/2 Status in Triple-negative Breast Cancer May Affect Responsiveness to Carboplatin
- Overcoming Resistance to ALK Inhibition in Lung Cancer
- Low-fat Diet and Breast Cancer
- Industry Payments to Physicians: Confronting Conflicts of Interest
- The Adverse Effects of Sarcoma Treatment in Cancer Survivors
- Gilteritinib Granted Orphan Drug Status for Acute Myeloid Leukemia
- Does Alcohol Raise the Risk of Bladder Cancer?
- Nivolumab Provides Durable Response in dMMR/MSI-H Colorectal Cancer
- Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer
- Some Patients With Terminal Cancer Receive Unnecessary Aggressive Treatment